Fulgent to Participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference

Rhea-AI Summary

Fulgent, Inc. (NASDAQ: FLGT) has announced that its management team will participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference on March 7, 2023, starting at 8:05 a.m. Eastern Time. A live webcast will be available on the company's website, with a replay accessible one hour after the event concludes.

Fulgent specializes in clinical diagnostics and therapeutic development, offering molecular diagnostic testing, genetic testing, and anatomic pathology services, aimed at enhancing patient care. The company is evolving from genomic diagnostics to a fully integrated precision medicine approach aimed at cancer treatment.

TEMPLE CITY, Calif.--(BUSINESS WIRE)-- Fulgent, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that members of its management team are scheduled to participate in the Raymond James & Associates’ 44^th Annual Institutional Investors Conference on Tuesday, March 7, 2023.

These representatives of the company will conduct a presentation beginning at approximately 8:05 a.m. Eastern Time (5:05 a.m. Pacific Time).

A live webcast of the session will be available on the Investor Relations section of the Fulgent Genetics website at ir.fulgentgenetics.com. A replay of the webcast will be accessible at the same location beginning approximately one hour following the completion of the event.

About Fulgent

Fulgent is a technology-based company with a well-established clinical diagnostic business and a therapeutic development business. Fulgent’s clinical diagnostic business offers molecular diagnostic testing services, comprehensive genetic testing, and high-quality anatomic pathology laboratory services designed to provide physicians and patients with clinically actionable diagnostic information to improve the quality of patient care. Fulgent’s therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company aims to transform from a genomic diagnostic business into a fully integrated precision medicine company.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230221005256/en/

Investor Relations Contacts:

The Blueshirt Group

Melanie Solomon, melanie@blueshirtgroup.com

Source: Fulgent, Inc.

FAQ

When will Fulgent, Inc. present at the Raymond James Conference?

Fulgent, Inc. will present on March 7, 2023, at 8:05 a.m. Eastern Time.

Where can I watch the Fulgent presentation live?

You can watch the live webcast of Fulgent's presentation on their Investor Relations website.

What is the focus of Fulgent's business?

Fulgent focuses on clinical diagnostics and therapeutic development, offering genetic testing and drug candidates for cancer treatment.

What time is Fulgent's presentation in Pacific Time?

The presentation will be at 5:05 a.m. Pacific Time.

How can I access the Fulgent webcast after the event?

A replay of the webcast will be available on the Fulgent website approximately one hour after the event.